Participants
borderline personality disorder, psychotic, bipolar disorder, schizoaffective disorder, schizophrenia, obsessive-compulsive disorder
SCID
Of the 118 participants who signed informed consent and screened, 33 were eligible and 28 were randomized (see Descriptive and demographic data.Lifetime Substance Use/Dependence(yes/no)The study was registered in clinicaltrials.gov (NCT02727998). Important to notice that while the primary outcome registered in the clinicaltrial.gov was PCL scores, one of the main outcomes in the NARSAD Independent Investigator Award (submitted before trial registration and data collection) was neural biomarker (see Supplemental material Original funded NARSAD grant application Aim 2). The neural mechanize is crucial toward an NIH grant application but this outcome was not registered in error.Exclusion criteria included a diagnostic history of bipolar disorder, borderline personality disorder, obsessive-compulsive disorder, schizophrenia or schizoaffective disorder, or current psychotic features as determined by the Structured Clinical Interview for DSM-IV (SCID) [